TAA-T cells for Lymphoma, Large B-Cell, Diffuse

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lymphoma, Large B-Cell, Diffuse+3 More
TAA-T cells - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will enroll patients who have already tried other treatments and failed (group A) or who are at high risk of their lymphoma coming back after an autologous hematopoeitic stem cell transplant (group B).

Eligible Conditions
  • Lymphoma, Large B-Cell, Diffuse
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Lymphoma, Hodgkins

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Tumor response to combination immunotherapy
Week 6
Incidence of Product-Emergent Adverse Events

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Nivolumab with TAA-T cell
1 of 1

Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: TAA-T cells · No Placebo Group · Phase 1

Nivolumab with TAA-T cellExperimental Group · 2 Interventions: TAA-T cells, Nivolumab · Intervention Types: Biological, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Catherine BollardLead Sponsor
13 Previous Clinical Trials
332 Total Patients Enrolled
Boyu Hu, MDPrincipal InvestigatorUTAH
1 Previous Clinical Trials
39 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
patients receive R-CHOP chemotherapy as standard of care Group B (patients without measurable disease) Patients with HL and DLBCL receive R-CHOP chemotherapy as standard of care The patients in Group A who have relapsed or refractory Hodgkin lymphoma or diffuse large B cell lymphoma will usually receive the R-CHOP chemotherapy treatment as the standard of care
Some cancer patients who are not eligible for an autologous stem cell transplant and have failed only one line of prior therapy may be candidates for a novel gene-modified T cell therapy.
If a person has failed more than one salvage treatment regimen, including a prior treatment with Brentuximab Vedotin, then they are considered a relapsed/refractory patient.
Group B includes patients with a high risk of relapse who have been treated with auto-HSCT.
Patients with < CMR/CR (by PET/CT) with initial treatment regimen.
The disease specific inclusion criteria are a set of medical conditions that must be met in order for a person to be eligible to participate in a clinical trial
Patients who have not responded to two previous lines of treatment, including both an autologous stem cell transplant and chimeric antigen receptor T cell therapy.
Systemic therapies to treat prior indolent lymphomas count towards previous DLBCL lines of therapy, unless the treatment was an anti-CD20 antibody monotherapy.
There is no increased risk of relapse after autologous HSCT.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.